中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Negative Beta Glucan in ICU Patients

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
Universidade Federal do Rio de Janeiro

关键词

抽象

This is a prospective study aimed at testing a strategy of early initiation of an antifungal agent to patients admitted to intensive care units (ICUs) at risk for invasive candidiasis. Score system have been developed to identify groups at very high risk for the development of candidemia/invasive candidiasis in the ICU. These scoring system have used clinical information with or without data on Candida colonization, and have shown reasonable correlation with candidemia/invasive candidiasis. More recently, a biomarker - detection of 1,3-beta-D-glucan in the serum - has been tested in the early diagnosis of candidiasis. The incorporation of biomarkers such as beta-D-glucan could help clinicians to select a group at higher risk for candidemia, and despite the fact that these tests may give false-positive results, their negative predictive value could be of great help.
Therefore, the objectives of this study are:
1. To assess the frequency of positive biomarkers in ICU patients at high risk to develop invasive candidiasis/candidemia;
2. To test the strategy of early discontinuation of antifungal therapy based on repeatedly negative blood cultures and 1,3 beta-D-glucan in the serum.

描述

Entry criteria are: In the ICU for >2 days AND systemic antibiotics >2 days OR central venous catheter for >days AND at least two of the following: total parenteral nutrition, dialysis, surgery, pancreatitis, receipt of corticosteroids, receipt of other immunosuppressive agents. In addition, patients must have a clinical sign of infection (either one of the following): fever, hypothermia, hypotension, unexplained acidosis, or unexplained elevation in C-reactive protein.

Eligible patients will be enrolled after signing an informed consent and will have blood obtained for culture and determination of 1,3 beta-D-glucan serum levels for 3 days, and will start anidulafungin IV.

If all tests are negative, anidulafungin will be discontinued on day 4. If 1,3 beta-D-glucan is positive (>80 pg/ml) and / or blood cultures are positive for Candida species, anidulafungin will be continued for >14 days.

日期

最后验证: 03/31/2019
首次提交: 11/19/2012
提交的预估入学人数: 11/25/2012
首次发布: 11/26/2012
上次提交的更新: 04/17/2019
最近更新发布: 07/07/2019
首次提交结果的日期: 11/29/2015
首次提交质量检查结果的日期: 04/17/2019
首次发布结果的日期: 07/07/2019
实际学习开始日期: 10/31/2012
预计主要完成日期: 11/30/2013
预计完成日期: 11/30/2013

状况或疾病

Candidemia

干预/治疗

Drug: Anidulafungin

相 4

手臂组

干预/治疗
Experimental: Anidulafungin
Patients at risk will receive therapy with anidulafungin
Drug: Anidulafungin
Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

- In the ICU for >2 days AND

- Systemic antibiotics on days 1-3 of ICU OR

- Central venous catheter on days 1-3 of ICU

- AND at least 2 of:

- Total parenteral nutrition on days 1-3 of ICU

- Any dialysis on days 1-3 of ICU

- Major surgery in the 7 days before admission in the ICU

- Pancreatitis in the 7 days before admission in the ICU

- Use of corticosteroids for at least 3 days in the 7 days before admission

- Use of other immunosuppressive agents in the 7 days before admission in the ICU

- In addition, the patient must have at least one of the following:

- Fever (axillary temperature >37.5 oC)

- Hypothermia (axillary temperature <35 oC)

- Hypotension

- Unexplained acidosis

- Unexplained elevation in C-reactive protein

Exclusion Criteria:

- Antifungal for >3 days

- Allergy to an echinocandin

结果

主要结果指标

1. Evaluate the Ocurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin [30 days]

The main interest is to evaluate the ocurrence of candidemia in patients with negative 1,3 beta-D-glucan who discontinue anidulafungin

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge